PharmaMar

Branded Legacy, Inc. Significantly Expands Asset Portfolio and Production Capacity Through Successful Acquisition of Sycamore BioPharma, Inc.

Retrieved on: 
Tuesday, March 12, 2024
Sycamore, Editor-in-chief, Growth, PHD, Biotechnology, Drug discovery, Patient, Research, Environmental technology, Acquisition, Cancer, Mentorship, DSM-IV codes, University, GMP, Clinical trial, Infection, Medical school, Adjunct, PharmaMar, Biomedical sciences, Family, Marketing, FDA, Biochimica et Biophysica Acta, Pharmaceutical industry

MELBOURNE, Fla., March 12, 2024 /PRNewswire/ -- Branded Legacy (OTC.PK: BLEG), Inc., a trailblazing BioTech holdings company, proudly announces the strategic acquisition of Sycamore BioPharma, Inc, a distinguished developer of plant-based pharmaceuticals. This strategic milestone not only fortifies Branded Legacy's standing as a prominent player in the biotech sector but also secures assets exceeding $2 million, along with key personnel crucial for advancing clinical trials following this successful union.

Key Points: 
  • The acquisition brings forth over $500,000 in high-quality, ready-to-sell inventory and aligns seamlessly with Branded Legacy's dedication to quality, authenticity, and a commitment to natural ingredients.
  • David Oswald, CEO at Branded Legacy, Inc., expresses enthusiasm about the acquisition, stating, "Branded Legacy is thrilled to embrace Sycamore BioPharma into our family of companies.
  • Tyler Stone, President of Sycamore Biopharma, Inc., is also enthusiastic about the acquisition stating, "Branded Legacy brings significant strengths in areas where Sycamore BioPharma was seeing significant challenges.
  • The collaboration between Branded Legacy and Sycamore BioPharma is poised to unlock synergies across various business facets.

Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation

Retrieved on: 
Wednesday, September 20, 2023
Atezolizumab, Diabetes, Neoplasm, Doctor of Philosophy, ODA, National library, Patient, GC, Disease, Prostate cancer, Carcinoma, CD47, Hope, Research, ACHL, Lung cancer, NLM, Orphan drug, Death, Drug development, Diagnosis, Growth, Rare, FDA, Legislation, Civil service commission, ODD, Roche, Orphan Drug Act of 1983, PharmaMar, Cancer, NSCLC, Treatment of lung cancer, ES, Therapy, Stomach, ORR, European Commission, File, United States National Library of Medicine, MedImmune, Inc. v. Genentech, Inc., Clinical trial, Woman, Lung, Fast track (FDA), SCLC, American Cancer Society, Achilles, Melanoma, OTCQX, Orphan, EC, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, FTD, RET, Food, Breast cancer, Pharmaceutical industry, Medical imaging, Genentech, Pembrolizumab

NEW YORK, Sept. 20, 2023 /PRNewswire/ -- More than 30 million people in the United States suffer with a rare disease; most of them are receiving no current treatment. Supporting the development and evaluation of new treatments, particularly for rare diseases, is a key priority for the U.S. Food & Drug Administration. As part of that process, the agency can grant Orphan Drug Designation (ODD) to a drug or biological product being developed to prevent, diagnose or treat a rare disease or condition. This designation is intended to spark innovation among biotech companies that are developing treatments for these patient populations, which by definition affect fewer than 200,000 people in the U.S., by providing incentives such as tax credits, user-fee exemptions and up to seven years of market exclusivity after FDA approval. Last month, Genprex Inc. (NASDAQ: GNPX) (Profile) was granted FDA orphan drug designation for its REQORSA(R) immunogene therapy in development for the treatment of small cell lung cancer (SCLC). The Phase 1/2 clinical trial, expected to dose the first patient in the fourth quarter of 2023, uses a combination of REQORSA and Genentech Inc.'s Tecentriq(R) as maintenance therapy in patients with extensive stage small cell lung cancer ("ES-SCLC") who did not develop tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment. Genprex joins other companies — including Roche Holding AG ADR (OTCQX: RHHBY), Jazz Pharmaceuticals PLC (NASDAQ: JAZZ), ALX Oncology Holdings Inc. (NASDAQ: ALXO) and Achilles Therapeutics PLC (NASDAQ: ACHL) — that have been granted ODD status or may seek ODD status as they work to develop treatments for rare diseases.

Key Points: 
  • Four decades after the Orphan Drug Act was passed, hundreds of 'orphan' drugs have been approved for use.
  • Genprex's REQORSA Immunogene Therapy has gained both Orphan Drug Designation and Fast Track Designation.
  • Specifically, the report noted that 6,340 orphan drug designations were granted, representing drug development for 1,079 rare diseases.
  • For companies looking to help those in the underserved rare-disease space, an Orphan Drug Designation is the ideal pathway to progress.

Pathways to Progress: How Orphan Drug Designation Sparks Biotech Transformation

Retrieved on: 
Wednesday, September 20, 2023
Atezolizumab, Diabetes, Neoplasm, Doctor of Philosophy, ODA, National library, Patient, GC, Disease, Prostate cancer, Carcinoma, CD47, Hope, Research, ACHL, Lung cancer, NLM, Orphan drug, Death, Drug development, Diagnosis, Growth, Rare, FDA, Legislation, Civil service commission, ODD, Roche, Orphan Drug Act of 1983, PharmaMar, Cancer, NSCLC, Treatment of lung cancer, ES, Therapy, Stomach, ORR, European Commission, File, United States National Library of Medicine, MedImmune, Inc. v. Genentech, Inc., Clinical trial, Woman, Lung, Fast track (FDA), SCLC, American Cancer Society, Achilles, Melanoma, OTCQX, Orphan, EC, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, FTD, RET, Food, Breast cancer, Pharmaceutical industry, Medical imaging, Genentech, Pembrolizumab

NEW YORK, Sept. 20, 2023 /PRNewswire/ -- More than 30 million people in the United States suffer with a rare disease; most of them are receiving no current treatment. Supporting the development and evaluation of new treatments, particularly for rare diseases, is a key priority for the U.S. Food & Drug Administration. As part of that process, the agency can grant Orphan Drug Designation (ODD) to a drug or biological product being developed to prevent, diagnose or treat a rare disease or condition. This designation is intended to spark innovation among biotech companies that are developing treatments for these patient populations, which by definition affect fewer than 200,000 people in the U.S., by providing incentives such as tax credits, user-fee exemptions and up to seven years of market exclusivity after FDA approval. Last month, Genprex Inc. (NASDAQ: GNPX) (Profile) was granted FDA orphan drug designation for its REQORSA(R) immunogene therapy in development for the treatment of small cell lung cancer (SCLC). The Phase 1/2 clinical trial, expected to dose the first patient in the fourth quarter of 2023, uses a combination of REQORSA and Genentech Inc.'s Tecentriq(R) as maintenance therapy in patients with extensive stage small cell lung cancer ("ES-SCLC") who did not develop tumor progression after receiving Tecentriq and chemotherapy as initial standard treatment. Genprex joins other companies — including Roche Holding AG ADR (OTCQX: RHHBY), Jazz Pharmaceuticals PLC (NASDAQ: JAZZ), ALX Oncology Holdings Inc. (NASDAQ: ALXO) and Achilles Therapeutics PLC (NASDAQ: ACHL) — that have been granted ODD status or may seek ODD status as they work to develop treatments for rare diseases.

Key Points: 
  • Four decades after the Orphan Drug Act was passed, hundreds of 'orphan' drugs have been approved for use.
  • Genprex's REQORSA Immunogene Therapy has gained both Orphan Drug Designation and Fast Track Designation.
  • Specifically, the report noted that 6,340 orphan drug designations were granted, representing drug development for 1,079 rare diseases.
  • For companies looking to help those in the underserved rare-disease space, an Orphan Drug Designation is the ideal pathway to progress.

GLOBAL SARCOMA THERAPY NOW LISTED ON PHARMACEUTICAL BENEFITS SCHEME

Retrieved on: 
Monday, July 31, 2023
Lead, Tobacco Products Scientific Advisory Committee, RCA, Medicine, Trabectedin, Sarcoma, Survival, Pharmaceutical Benefits Scheme, PharmaMar, Cancer, Attention, Patient, PBS, Liposarcoma, Ophthalmology, Oncology, Therapy, Neurology, News, Disease, Pharmaceutical industry, Medical imaging, Health insurance, Nursing

SINGAPORE, July 31, 2023 /PRNewswire/ -- AUSTRALIAN cancer patients who have been diagnosed with rare soft tissue sarcomas will now have affordable access to a global therapy shown to improve survival, following its listing on the Pharmaceutical Benefits Scheme (PBS).

Key Points: 
  • SINGAPORE, July 31, 2023 /PRNewswire/ -- AUSTRALIAN cancer patients who have been diagnosed with rare soft tissue sarcomas will now have affordable access to a global therapy shown to improve survival, following its listing on the Pharmaceutical Benefits Scheme (PBS).
  • So, for patients to have access to a global therapy in their own country is wonderful news."
  • "For too long, sarcoma patients have been unable to access all therapies which may provide benefit," he said.
  • YONDELIS is marketed in Australia by independent pharmaceutical company Specialised Therapeutics, under an exclusive license arrangement with international partner PharmaMar.

Nouscom Strengthens Leadership Team with the Appointments of Sven Gogov, MD, as Chief Medical Officer and Maria Arce-Tomas, PhD, as VP, Head of Regulatory Affairs

Retrieved on: 
Friday, September 9, 2022
AstraZeneca, Maria, Novartis, University, Regulation, Cancer, Tumor microenvironment, Doctor of Philosophy, Imperial College London, University Health Network, Veteran, GE Healthcare, Clinical research, GSK, Novo Nordisk, University of Valencia Science Park, Abbott, Lead, LinkedIn, Department, CMO, Goal, Pembrolizumab, Bachelor of Pharmacy, MD, Leadership, Biotechnology, Regulatory affairs, Therapy, Immunotherapy, ASCO, Oncology, FDA, Neoplasm, Drug, King's College London, PharmaMar, OSI Pharmaceuticals, Patient, Pharmaceutical industry, Vaccine, Science, Toxicology, Biochemistry, Pharmacy, Takeda

Gogov will join the executive management team and be responsible for the development of the companys clinical project portfolio.

Key Points: 
  • Gogov will join the executive management team and be responsible for the development of the companys clinical project portfolio.
  • "I am also delighted to welcome Maria as the newly appointed Vice President, Head of Regulatory Affairs.
  • Sven Gogov, MD, is an experienced global clinical development leader bringing over 15 years of pharmaceutical oncology experience and regulatory interactionsto Nouscom.
  • Maria joins Nouscom from PharmaMar where she was Global Head of Regulatory Affairs responsible for the entire product portfolio of the PharmaMar Group.

Nouscom Strengthens Leadership Team with the Appointments of Sven Gogov, MD, as Chief Medical Officer and Maria Arce-Tomas, PhD, as VP, Head of Regulatory Affairs

Retrieved on: 
Friday, September 9, 2022
AstraZeneca, Maria, Novartis, University, Regulation, Cancer, Tumor microenvironment, Doctor of Philosophy, Imperial College London, University Health Network, Veteran, GE Healthcare, Clinical research, GSK, Novo Nordisk, University of Valencia Science Park, Abbott, Lead, LinkedIn, Department, CMO, Goal, Pembrolizumab, Bachelor of Pharmacy, MD, Leadership, Biotechnology, Regulatory affairs, Therapy, Immunotherapy, ASCO, Oncology, FDA, Neoplasm, Drug, King's College London, PharmaMar, OSI Pharmaceuticals, Patient, Pharmaceutical industry, Vaccine, Science, Toxicology, Biochemistry, Pharmacy, Takeda

Gogov will join the executive management team and be responsible for the development of the companys clinical project portfolio.

Key Points: 
  • Gogov will join the executive management team and be responsible for the development of the companys clinical project portfolio.
  • "I am also delighted to welcome Maria as the newly appointed Vice President, Head of Regulatory Affairs.
  • Sven Gogov, MD, is an experienced global clinical development leader bringing over 15 years of pharmaceutical oncology experience and regulatory interactionsto Nouscom.
  • Maria joins Nouscom from PharmaMar where she was Global Head of Regulatory Affairs responsible for the entire product portfolio of the PharmaMar Group.

Valued to be $8.4 Billion by 2026, Marine Biotechnology Slated for Robust Growth Worldwide

Retrieved on: 
Monday, July 4, 2022
Agriculture, Plant, PharmaMar, Research, Adoption, Pesticide, Coral, Marketing, COVID-19, Growth, Industry, Aquaculture, Bacteria, Gesellschaft mit beschränkter Haftung, Lists of diseases, Environment, Industrialisation, Degenerative disease, Food industry, Biodiversity, Medication, Fishery, Microalgae, BASF, Biofuel, SAN, Isolation, Therapy, Investment, CAGR, Solution, Players, Diabetes, Marine viruses, Government, BASF SE, Intelligence, Forecasting, Internet, Disorder, Pollution, Cosmetics, Drug discovery, SE, Enzyme, Nutrient, GIA, Awareness, Biopolymer, Biomaterial, Pharmaceutical industry, Seaweed, Food, Technology

Increasing use of marine ingredients in food, agriculture and cosmetic industries is fostering growth in the marine biotechnology marketplace.

Key Points: 
  • Increasing use of marine ingredients in food, agriculture and cosmetic industries is fostering growth in the marine biotechnology marketplace.
  • Agricultural applications include pesticides, plant growth regulators and seed coated fungicides comprise another high growth market for marine biotechnology.
  • With marine bioresources emerging as major sources of new chemical and biological processes, marine biotechnology is being considered as a means to encourage innovation.
  • Realizing the significance of marine biotechnology, international agreements and conventions have been forged to provide a framework for conserving marine biodiversity and to facilitate sharing of marine bioresources.

Global Marine Biotechnology Market to Reach $5 Billion by 2026

Retrieved on: 
Monday, March 21, 2022
Risk, CAGR, Nitrogen, BASF SE, Biofouling, Gesellschaft mit beschränkter Haftung, Forecasting, Research, Environment, Agriculture, Lactone, Chitin, Isolation, Population, Players, Marketing, SE, Chitosan, Biomaterial, Aquaculture, Shellfish, Health, PharmaMar, Food, Acetal, Alkaloid, Genetic engineering, Bio, Therapy, Seaweed, Investment, Fertilizer, Growth, Internet, Intelligence, BASF, Electricity, Administration, Ecosystem, Phenomics, SAN, Adoption, Whale, Biopolymer, Tuna, Quinone, Aether, PCR, Salmon, Food industry, Coral Reefs, Microalgae, Drug discovery, Biomass, Safety, Medication, GIA, COVID-19, Biophysical environment, Pharmaceutical industry, Fine chemical, Peptide, Technology

SAN FRANCISCO, March 21, 2022 /PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Marine Biotechnology - Global Market Trajectory & Analytics" .

Key Points: 
  • SAN FRANCISCO, March 21, 2022 /PRNewswire/ -- A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Marine Biotechnology - Global Market Trajectory & Analytics" .
  • The global bioplastics and biopolymers market is increasingly looking towards new advances made in marine biotechnology to develop completely new class of biodegradable biopolymers.
  • Amid the COVID-19 crisis, the global market for Marine Biotechnology estimated at US$3.7 Billion in the year 2022, is projected to reach a revised size of US$5 Billion by 2026, growing at a CAGR of 5.8% over the analysis period.
  • The U.S. Market is Estimated at $1.1 Billion in 2022, While China is Forecast to Reach $481.8 Million by 2026
    The Marine Biotechnology market in the U.S. is estimated at US$1.1 Billion in the year 2022.

Life Science Alliance journal publishes results of plitidepsin in patients with COVID-19, which includes additional data on its antiviral activity against Delta and Omicron variants

Retrieved on: 
Tuesday, January 11, 2022
Lung, Patient, Pneumonia, Mount Sinai, Life Science Alliance, MSE, European Molecular Biology Organization, Clinical trial, COVID-19, Icahn School of Medicine at Mount Sinai, Severe acute respiratory syndrome coronavirus 2, Safety, Therapeutic index, PHM, National university, Disease, Department, EMBO, Animal, Rockefeller University, Cold, Viral load, Company, Internal medicine, G.H. Raisoni Department of Microbiology and Biotechnology, European, Hospital, Phase, Hospital das Clínicas, Cold Spring Harbor Laboratory, PharmaMar, Delta, Pulse oximetry, Coronavirus, Omicron, Pharmaceutical industry, Microbiology

MADRID, Jan. 11, 2022 /PRNewswire/ -- PharmaMar (MSE:PHM) has announced today the publication of an article in the Life Science Alliance journal, entitled "Pre-clinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19"[1] which includes a study on the in vitro activity of plitidepsin against the main SARS-CoV-2 variants, including the current Omicron variant.

Key Points: 
  • - PharmaMar confirms in vitroactivity of plitidepsin against several variants, including Delta and Omicron.
  • - The Life Science Alliance journal is co-founded by the Rockefeller University, the European Molecular Biology Organization (EMBO) and Cold Spring Harbor Laboratory.
  • The article also reviews data from the APLICOV-PC clinical trial, which demonstrated the safety of plitidepsin in patients with COVID-19 requiring hospital admission.
  • Jos Mara Fernndez Sousa-Faro, Ph.D., PharmaMar's Chairman stated "all the data we have seen so far with plitidepsin corroborate our initial hypothesis about its antiviral activity.

Life Science Alliance journal publishes results of plitidepsin in patients with COVID-19, which includes additional data on its antiviral activity against Delta and Omicron variants

Retrieved on: 
Tuesday, January 11, 2022
Lung, Patient, Pneumonia, Mount Sinai, Life Science Alliance, MSE, Clinical trial, COVID-19, Icahn School of Medicine at Mount Sinai, Severe acute respiratory syndrome coronavirus 2, Therapeutic index, Safety, PHM, Disease, Department, Animal, Viral load, Internal medicine, G.H. Raisoni Department of Microbiology and Biotechnology, Phase, Hospital, Hospital das Clínicas, PharmaMar, Delta, Pulse oximetry, Coronavirus, Omicron, Pharmaceutical industry, Microbiology

According to the final data published in this article, plitidepsin has been shown to have a potent antiviral activity in all variants at very low (nanomolar) concentrations, with a positive in vitro therapeutic index.

Key Points: 
  • According to the final data published in this article, plitidepsin has been shown to have a potent antiviral activity in all variants at very low (nanomolar) concentrations, with a positive in vitro therapeutic index.
  • Laboratory in vivo studies have also demonstrated a preferential distribution of plitidepsin to lung tissue, which is the organ primarily affected in patients with COVID-19.
  • The article also reviews data from the APLICOV-PC clinical trial, which demonstrated the safety of plitidepsin in patients with COVID-19 requiring hospital admission.
  • Jos Mara Fernndez Sousa-Faro, Ph.D., PharmaMar's Chairman stated "all the data we have seen so far with plitidepsin corroborate our initial hypothesis about its antiviral activity.